170 related articles for article (PubMed ID: 35761110)
1. Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece.
Yavropoulou MP; Makras P; Athanasakis K; Bournia VK; Mathioudakis K; Tsolakidis A; Kassi E; Kaltsas G; Mitrou P; Sfikakis PP
Arch Osteoporos; 2022 Jun; 17(1):86. PubMed ID: 35761110
[TBL] [Abstract][Full Text] [Related]
2. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
3. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
Kamata Y; Minota S
Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
[TBL] [Abstract][Full Text] [Related]
4. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
[TBL] [Abstract][Full Text] [Related]
5. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
Naik-Panvelkar P; Norman S; Elgebaly Z; Elliott J; Pollack A; Thistlethwaite J; Weston C; Seibel MJ
BMC Fam Pract; 2020 Feb; 21(1):32. PubMed ID: 32050909
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
Hiligsmann M; Reginster JY
Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
[TBL] [Abstract][Full Text] [Related]
9. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
Olsen KR; Hansen C; Abrahamsen B
Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
[TBL] [Abstract][Full Text] [Related]
10. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
11. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
Usui T; Funagoshi M; Seto K; Ide K; Tanaka S; Kawakami K
Arch Osteoporos; 2018 May; 13(1):54. PubMed ID: 29725863
[TBL] [Abstract][Full Text] [Related]
12. Dispensing anti-osteoporotic drugs changed during the COVID-19 pandemic.
Kocijan R; Stockinger T; Haschka J; Reichardt B; Resch H; Zwerina J; Behanova M
Bone; 2022 Sep; 162():116477. PubMed ID: 35779846
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of osteoporosis treatments in Germany.
O'Kelly J; Bartsch R; Kossack N; Borchert J; Pignot M; Hadji P
Arch Osteoporos; 2022 Aug; 17(1):119. PubMed ID: 36044096
[TBL] [Abstract][Full Text] [Related]
14. Cost-effective osteoporosis treatment thresholds in Greece.
Makras P; Athanasakis K; Boubouchairopoulou N; Rizou S; Anastasilakis AD; Kyriopoulos J; Lyritis GP
Osteoporos Int; 2015 Jul; 26(7):1949-57. PubMed ID: 25740208
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of eligibility for denosumab in patients presenting with osteoporotic fractures and renal impairment treated by orthogeriatric service at Middlemore Hospital.
Kang MY; Besley J; Sun T; Paul S
N Z Med J; 2020 May; 133(1515):16-24. PubMed ID: 32438373
[TBL] [Abstract][Full Text] [Related]
16. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
17. Use of anti-osteoporotic drugs in central Norway after a forearm fracture.
Hoff M; Skurtveit S; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Abrahamsen B; Schei B
Arch Osteoporos; 2015; 10():235. PubMed ID: 26334427
[TBL] [Abstract][Full Text] [Related]
18. Trends in anti-osteoporotic medication utilization following fragility fracture in the USA from 2011 to 2019.
Agarwal AR; Cohen JS; Jorgensen A; Thakkar SC; Srikumaran U; Golladay GJ
Osteoporos Int; 2023 Feb; 34(2):379-385. PubMed ID: 36462054
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Morkos M; Mahrous P; Casagrande A; Go MT; Husni H; Hanna M; Goel M; Bedrose S; Li D; Baim S
Endocr Pract; 2022 Oct; 28(10):1078-1085. PubMed ID: 35787466
[TBL] [Abstract][Full Text] [Related]
20. Using Osteoporosis Therapies in Combination.
McClung MR
Curr Osteoporos Rep; 2017 Aug; 15(4):343-352. PubMed ID: 28667435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
